Diabetic kidney disease has a high global disease burden and substantially increases the
risk of kidney failure and cardiovascular events. Despite treatment, there is substantial …

Background: The connection between uric acid (UA) and renal impairment is well known
due to the urate capacity to precipitate within the tubules or extra-renal system. Emerging …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Diabetic kidney disease is the leading cause of kidney failure worldwide; in the USA, it
accounts for over 50% of individuals entering dialysis or transplant programmes. Unlike …

Background Dapagliflozin reduces the risk of kidney failure and heart failure in patients with
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …

SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

Diabetic kidney disease (DKD) is one of the fastest growing causes of chronic kidney
disease and associated morbidity and mortality. Preclinical research has demonstrated the …

Abstract Coronavirus disease 2019 (COVID‐19) is a recent pandemic caused by severe
acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a novel coronavirus. Diabetes …